All Articles

Evidence-Based Science
by a PharmD

Search Articles →
Autoimmune

CAR-T Cell Therapy Is Resetting Autoimmune Disease — What the 2026 NEJM Data Actually Shows

CD19-targeted CAR T-cell therapy has produced drug-free remission in refractory lupus, myositis, and systemic sclerosis patients. A pharmacist breaks down the mechanism, the case series data, and what it means if you have a severe autoimmune condition.

12 min read June 2026
Continue Reading
Longevity

Senolytics in 2026: From Blunt Instruments to Precision Senotherapy — What the Latest Research Changes

First-generation senolytics like dasatinib + quercetin proved the concept but hit real limits. A 2026 npj Aging review maps the shift to precision senotherapy — tissue-targeted, marker-guided, and far less toxic. Here's what it means for anyone tracking the longevity space.

11 min read May 2026
Read
Supplements

Biomarker-Guided Supplementation Cuts Inflammation by Up to 46%: What the 2026 Study Found — and What It Actually Means

A 12-week study of personalized, biomarker-directed supplementation showed CRP reductions of 33–46% and homocysteine drops of 29–37% across all age and sex groups. A pharmacist reads between the lines of what's genuinely useful here versus what's being overstated.

9 min read May 2026
Read
Pharmacogenomics

CYP2D6 and CYP2C19: What Your Metabolizer Status Actually Means for Your Medications and Supplements

Up to 10% of people are CYP2D6 poor metabolizers. Up to 30% are CYP2C19 intermediate or poor metabolizers. These variants affect how dozens of medications work in your body — and almost no one has been told. A pharmacist explains what the clinical evidence says and what to do about it.

13 min read April 2026
Read
Autoimmune

Ginger Supplements and Autoimmune Disease: The Neutrophil NET Mechanism That Changes How to Think About This

New research reveals ginger's mechanism in autoimmune disease isn't anti-inflammatory in the traditional sense — it makes neutrophils more resistant to forming NETs (neutrophil extracellular traps), the microscopic structures that drive lupus, antiphospholipid syndrome, and RA flares. The pharmacist's breakdown of the evidence and the dose that's actually studied.

8 min read April 2026
Read
Autoimmune

The Gut-Immune Axis: How Intestinal Permeability Drives Autoimmune Flares — and What the Evidence Says About Fixing It

Emerging research in mucosal immunology has confirmed what many clinicians suspected: a compromised intestinal barrier doesn't just cause digestive discomfort — it's a primary driver of systemic autoimmune activation. Here's the pharmacist's breakdown of the science, and the supplement and lifestyle strategies with the strongest evidence base.

14 min read June 2025
Continue Reading